Business Context and Reporting Period
This Form 8-K filing by Protagonist Therapeutics, Inc. (PTGX) was submitted on June 27, 2023, regarding a corporate governance matter. The report addresses a vacancy on the company's Audit Committee following the Annual Meeting of Stockholders held on May 25, 2023, where Sarah Noonberg, M.D., Ph.D. did not stand for re-election.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding board composition.
Material Changes
The material change reported is the company's non-compliance with Nasdaq Listing Rule 5605, which mandates that the audit committee be comprised of at least three independent directors. On June 27, 2023, Nasdaq confirmed the company is no longer in compliance due to the vacancy.
Outlook, Risks, and Management Commentary
- Cure Period: The company intends to rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4) to reestablish compliance.
- Deadline: The cure period extends until the earlier of the company's next annual meeting of stockholders or May 27, 2024.
- Management Action: The Board of Directors is actively identifying and selecting a qualified independent director to fill the vacancy and intends to fully comply with requirements by the end of the cure period.
- Risk: Failure to appoint a qualified member within the cure period could result in delisting or other enforcement actions by Nasdaq.
Investor Verification Checklist
- Confirm the timeline for the appointment of a new independent Audit Committee member.
- Monitor future filings to ensure the vacancy is filled before the May 27, 2024 deadline.
- Verify that the new appointee meets the specific independence criteria defined in Nasdaq Listing Rule 5605.